Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10462
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSartor, Daniela Men
dc.contributor.authorVerberne, Anthony J Men
dc.date.accessioned2015-05-15T23:55:02Z
dc.date.available2015-05-15T23:55:02Z
dc.date.issued2007-11-16en
dc.identifier.citationNaunyn-schmiedeberg's Archives of Pharmacology 2007; 376(4): 241-52en
dc.identifier.govdoc18008064en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10462en
dc.description.abstractCholecystokinin (CCK) elicits a sympathetic vasomotor reflex that is implicated in gastrointestinal circulatory control. We sought to determine (1) the site in the solitary tract nucleus (NTS) responsible for mediating this reflex and (2) the possible involvement of excitatory amino acid (EAA) receptors. In addition, we sought to determine whether the NTS site responsible for mediating the baroreflex (phenylephrine, PE, 10 microg/kg i.v.) and the von Bezold-Jarisch reflex (phenylbiguanide, PBG, 10 microg/kg i.v) overlap with that involved in the CCK-induced reflex (CCK, 4 microg/kg, i.v.), and to compare the relative importance of NMDA and non-NDMA receptors in these reflexes. In separate experiments, the effects of PE, PBG, and CCK on mean arterial blood pressure, heart rate, and splanchnic sympathetic nerve discharge were tested before and after bilateral microinjection into the NTS of the gamma-aminobutyric acid(A) (GABA(A)) agonist muscimol, the EAA antagonist kynurenate, the NMDA receptor antagonist D: (-)-2-amino-5-phosphopentanoic acid (AP-5), the non-NMDA receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX), AP-5 + NBQX, or vehicle. While all treatments (except vehicle) significantly attenuated/abolished/reversed the splanchnic sympathoinhibitory responses to PE, PBG, and CCK, the extent of blockade varied between the different treatment groups. Both NMDA and non-NMDA receptors were essential to the baroreflex and the von Bezold-Jarisch reflex, whereas the CCK reflex was more dependent on non-NMDA receptors. Muscimol, kynurenate, and AP-5 + NBQX significantly attenuated the bradycardic responses to PE and PBG (P < 0.05), whereas AP-5, NBQX, or vehicle did not. The bradycardic responses to CCK remained intact after all treatments. These results suggest that while there is overlap in the area of the NTS responsible for eliciting all three reflexes, NMDA and non-NMDA receptors are recruited differentially for the full expression of these reflexes. The CCK-induced sympathoinhibitory reflex is unique in that it relies predominantly on non-NMDA receptors in the NTS and elicits bradycardic effects that are independent of the NTS.en
dc.language.isoenen
dc.subject.other2-Amino-5-phosphonovalerate.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherBiguanides.pharmacologyen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCholecystokinin.pharmacologyen
dc.subject.otherGABA Agonists.pharmacologyen
dc.subject.otherHeart Rate.drug effectsen
dc.subject.otherKynurenic Acid.pharmacologyen
dc.subject.otherMaleen
dc.subject.otherMuscimol.pharmacologyen
dc.subject.otherPhenylephrine.pharmacologyen
dc.subject.otherQuinoxalines.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherReceptors, AMPA.antagonists & inhibitors.physiologyen
dc.subject.otherReceptors, Kainic Acid.antagonists & inhibitors.physiologyen
dc.subject.otherReceptors, N-Methyl-D-Aspartate.antagonists & inhibitors.physiologyen
dc.subject.otherReflex.physiologyen
dc.subject.otherSolitary Nucleus.physiologyen
dc.subject.otherSynaptic Transmission.drug effectsen
dc.titleThe role of NMDA and non-NMDA receptors in the NTS in mediating three distinct sympathoinhibitory reflexes.en
dc.typeJournal Articleen
dc.identifier.journaltitleNaunyn-Schmiedeberg's archives of pharmacologyen
dc.identifier.affiliationDepartment of Medicine, Clinical Pharmacology and Therapeutics Unit, Austin Health, University of Melbourne, Heidelberg, Victoria, 3084, Australiaen
dc.identifier.doi10.1007/s00210-007-0203-5en
dc.description.pages241-52en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/18008064en
dc.type.austinJournal Articleen
item.grantfulltextopen-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
18008064.pdf58.13 kBAdobe PDFView/Open
Show simple item record

Page view(s)

8
checked on Jan 29, 2023

Download(s)

36
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.